Invesco Biotechnology & Genome ETF's Invesco Biotechnology & Genome ETF (PBE) has disclosed 30 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-04-30. The current portfolio value is calculated to be $246.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 24%.
Invesco Biotechnology & Genome ETF (PBE)'s
Total Assets is $293.37 Mil , Total Liabilities is $47.56 Mil , Net Assets is $245.81 Mil.
In Invesco Biotechnology & Genome ETF (PBE)'s current portfolio as of 2024-04-30, the top 5 holdings are
Neurocrine Biosciences Inc (NBIX), Biogen Inc (BIIB), Amgen Inc (AMGN), Regeneron Pharmaceuticals Inc (REGN) and Vertex Pharmaceuticals Inc (VRTX),
not including call and put options.
Invesco Biotechnology & Genome ETF (PBE) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Invesco Biotechnology & Genome ETF (PBE), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Invesco Biotechnology & Genome ETF (PBE), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Invesco Biotechnology & Genome ETF.